Gene editing market may nearly triple to $30.5b by 2033

Asia Pacific is seen as fastest-growing region.

The global gene editing market is projected to grow to $30.5b by 2033 due to rapid advances in CRISPR/Cas9, base editing, and prime editing.

These advancements have improved precision and reduced off-target effects, pushing the technology from lab research into clinical treatment for cancer, rare diseases, and inherited disorders.

According to a Persistence Market Research report, as of 2025, more than 250 gene-editing clinical trials are underway globally, with over 150 currently active.

CRISPR/Cas9 remains the dominant technology, accounting for approximately 75% of market revenue, owing to its efficiency and broad application across therapeutics, agriculture, and research.

Zinc finger nucleases, whilst a smaller segment, are the fastest-growing product category, gaining traction in targeted cell therapies and complex genome engineering where high specificity is required.

By application, cell line engineering leads the market with more than 40% share, driven by rising demand for biologics production and drug discovery.

North America holds the largest regional share at approximately 52% of global revenue, underpinned by a mature biotechnology ecosystem, strong clinical research infrastructure, and heavy venture capital investment.

Meanwhile, Asia Pacific is the fastest-growing region, with China, India, South Korea, and Japan expanding biotechnology infrastructure and precision medicine initiatives through government funding and cost-efficient manufacturing.